Blinatumomab in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia: RIALTO expanded access study final analysis
Sign Up to like & getrecommendations! Published in 2022 at "Blood Advances"
DOI: 10.1182/bloodadvances.2021005579
Abstract: Key Points Blinatumomab was associated with low incidence of grade 3 or 4 cytokine release syndrome (n = 2; 1.8%) and neurologic events (n = 4; 3.6%). The best blinatumomab outcomes were seen in patients… read more here.
Keywords: blinatumomab pediatric; refractory cell; cell acute; pediatric relapsed ... See more keywords
Insights from the Greek experience of the use of Blinatumomab in pediatric relapsed and refractory acute lymphoblastic leukemia patients.
Sign Up to like & getrecommendations! Published in 2020 at "Neoplasma"
DOI: 10.4149/neo_2020_200128n93
Abstract: Pediatric refractory or relapsed acute lymphoblastic leukemia (ALL) poses unique therapeutic challenges, with novel immunotherapy approaches offering potential cure opportunities. In this frame, the use of Blinatumomab may induce durable remissions, serving as a successful… read more here.
Keywords: blinatumomab; acute lymphoblastic; use blinatumomab; pediatric relapsed ... See more keywords